There might be people who are interested in this but have not seen it advertised: there is still place available at a not-too-expensive fragment-based drug design meeting organised by the Royal Society of Chemistry. It takes place March 4th and 5th at our place (AstraZeneca, Alderley Park, Cheshire UK). Further details (programme, pdf of final circular) are available via www.confsec.co.uk
Richard Pauptit Associate Director and Principal Scientist Cell, Protein, & Structural Sciences AstraZeneca 50S36, Mereside, Alderley Park Macclesfield SK10 4TG Cheshire, UK. email: richard.paup...@astrazeneca.com tel: +44 1625 516135 -------------------------------------------------------------------------- AstraZeneca UK Limited is a company incorporated in England and Wales with registered number: 03674842 and a registered office at 15 Stanhope Gate, London W1K 1LN. Confidentiality Notice: This message is private and may contain confidential, proprietary and legally privileged information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorised use or disclosure of the contents of this message is not permitted and may be unlawful. Disclaimer: Email messages may be subject to delays, interception, non-delivery and unauthorised alterations. Therefore, information expressed in this message is not given or endorsed by AstraZeneca UK Limited unless otherwise notified by an authorised representative independent of this message. No contractual relationship is created by this message by any person unless specifically indicated by agreement in writing other than email. Monitoring: AstraZeneca UK Limited may monitor email traffic data and content for the purposes of the prevention and detection of crime, ensuring the security of our computer systems and checking Compliance with our Code of Conduct and Policies.
